CYP
Delivery · Highdata caveat$66M2mo
Cynata Therapeutics
Biotechnology · Cell therapy
Clinical-stage biotech developing off-the-shelf iPSC-derived mesenchymal stem cell therapies via its Cymerus platform, with Phase 2/3 trials in GvHD and osteoarthritis.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.6M
Mar 2026 4C
Runway
2moCRITICAL
Based on Mar 2026 4C
Market Cap
$66M
Burn Rate
$2.2M/qtr
Mar 2026 4C
Shares Outstanding
243M
Pipeline Assets
6
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther2 June 2026
EU Positive Opinion on CYP-001 Paediatric Investigation Plan
Cynata Therapeutics received a Positive Opinion from the EMA's Paediatric Committee on its Paediatric Investigation Plan for CYP-001 in acute graft versus host disease, enabling progression toward EU Phase 3 trials. The agreed plan includes a single Phase 2/3 paediatric trial (~72 patients aged 28 days to 18 years) to follow the adult Phase 3 trial, with potential for adult Marketing Authorisation Application submission while paediatric trial is ongoing.
3M Price
CYP.ASX$0.265-22.1% 3M
Low $0.255High $0.365
Capital Raises & Buybacks
12mo dilution 2.5%12mo $2M1 raise
Current shares outstanding: 243M
Placement
2026-05-04placement
$1.5M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-05-07 · 4-day lag
Short position
0.00%
Shares short
0.0M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Stem Cell Res Ther2025-12· Cymerus MSCs
Catalysts (7)· 3 upcoming · 4 past
CYP-004 Phase 3 osteoarthritis top-line results
UpcomingExpectedarrow_upwardHigh30 June 2026
CYP-001 Phase 2 aGvHD top-line results
UpcomingConfirmedarrow_upwardHigh30 June 2026
CYP-004 Phase 3 osteoarthritis top-line results (SCUlpTOR)
UpcomingConfirmedarrow_upwardHigh30 June 2026
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High83/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High78/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 4 of 4 guided dates· rolling 2yr· of 7 tracked
Filed 2 of 2 4Cs on time· statutory deadline
What drove these scores · rolling 2yr
arrow_drop_down
1 burn spike — Quarter-on-quarter spend increase >50%
·
Proposed issue of securities - CYP — Delivered on time
·
Cynata Secures Commitments for $1.5m Placement — Delivered on time
·
Expected Timing of Clinical Trial Results — Delivered on time
·
EU Positive Opinion on CYP-001 Paediatric Investigation Plan — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (4/6 data points) — accuracy improves with more completed catalysts
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓Proposed issue of securities - CYP
On time
✓Cynata Secures Commitments for $1.5m Placement
On time
✓Expected Timing of Clinical Trial Results· readout — subject to clinical uncertainty— This announcement provides timing updates only, with no efficacy results disclosed yet. The Phase 3 SCUlpTOR trial (CYP-004) enrolled 321 patients with co-primary endpoints of pain and cartilage thickness change, with results expected June 2026. The Phase 2 CYP-001 trial enrolled 65 patients with Overall Response Rate at Day 28 as primary endpoint, with results expected late June or early July 2026.
On time
✓EU Positive Opinion on CYP-001 Paediatric Investigation Plan— Cynata Therapeutics received a Positive Opinion from the EMA's Paediatric Committee on its Paediatric Investigation Plan for CYP-001 in acute graft versus host disease, enabling progression toward EU Phase 3 trials. The agreed plan includes a single Phase 2/3 paediatric trial (~72 patients aged 28 days to 18 years) to follow the adult Phase 3 trial, with potential for adult Marketing Authorisation Application submission while paediatric trial is ongoing.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph2Active Not RecruitingEnrollment stale · 828d
CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)PlaceboCorticosteroids
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Graft Versus Host Disease, Acute
RandomizedQuadruple Blind18 Years+
Primary endpoint Overall response rate (ORR)
ENROL60
no manual snapshots — enter via record_enrollment.py
Announcements(16)
article
OtherPSauto_awesome
EU Positive Opinion on CYP-001 Paediatric Investigation Plan2 June 2026
expand_more169KB